1:24 Health Canada approves generic semaglutide for adults with type 2 diabetes Two generic versions of Ozempic and Wegovy are set to start arriving in Canadian pharmacies this week, which means ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Some Canadian ...

With questions already swirling about the actual affordability impact of the government’s drug purchasing portal, TrumpRx, the White House is updating the platform to address a key gap in the ...

The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...

The Trump administration on Monday said it is adding generic medications to its direct-to-consumer drug sales website, TrumpRx. The platform, which launched in February, is key to his administration's ...

President Trump announced the addition of 600 medicines to his online drugstore as he appeals to Americans concerned about high drug prices and affordability. By Rebecca Robbins President Trump said ...

India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Subscribe to read this story ad-free Get unlimited access to ...

Experts have informed that the Indian pharma has moved from volume-led generics to value plus innovation-led growth through strategic mergers and acquisitions (M&As) over the past one year. The ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is one of the best small-cap value stocks to buy. On April 20, ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) confirmed the Food and Drug Administration’s approval of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Patent expiry across API, formulation, and device IP is expected to catalyze biosimilar competition, expanding access while compressing pricing across pharmaceutical and device value chains.

Late last year, software automation firm UiPath, Inc. (PATH) traded as close as around $20. In January, sellers emerged, continuing to dump the stock in February. In March, when the company posted ...